Emerald Mutual Fund Advisers Trust Q4 2022 vs. Q1 2023 13F Holdings Comparison

Emerald Mutual Fund Advisers Trust is a mutual fund company that manages multiple mutual funds across different sectors like healthcare, finance, and energy. As a mutual fund company, Emerald Mutual Fund Advisers Trust is required to file a Form 13F with the Securities and Exchange Commission (SEC) four times a year. Form 13F is a report that shows the company's holdings in publicly traded companies in the US worth more than $100 million. This report is used by investors and analysts to track the stocks that mutual funds are buying and selling, and in which sectors they are most active.

In this article, we will be looking at Emerald Mutual Fund Advisers Trust's Q4 2022 and Q1 2023 13F holdings comparison. The report shows that the mutual fund company has made some significant changes to its holdings in the first quarter of 2023 compared to the previous quarter in 2022.

One of the most significant changes is Emerald Mutual Fund Advisers Trust's holdings in Lantheus Holdings Inc (LNTH). The company increased its holdings in LNTH by 24%, from 338,801 shares in Q4 2022 to 422,415 shares in Q1 2023. The value of the holdings also increased from $17,265,000 to $34,874,000. Lantheus Holdings is a company that specializes in developing, manufacturing, and commercializing diagnostic medical imaging agents.

Another notable change is in the company's holdings in Tenable Holdings Inc (TENB). Emerald Mutual Fund Advisers Trust increased its holdings in the company by a massive 260.5%, from 180,196 shares in Q4 2022 to 521,570 shares in Q1 2023. The value of the holdings also increased from $6,874,000 to $24,779,000. Tenable Holdings is a cybersecurity company that provides vulnerability management and network security solutions.

Furthermore, Emerald Mutual Fund Advisers Trust reduced its holdings in Replimune Group Inc (REPL) by 46% from 965,938 shares in Q4 2022 to 803,448 shares in Q1 2023. The value of the holdings also decreased from $26,273,000 to $14,188,000. Replimune Group is a biotechnology company that develops oncolytic immunotherapy products for cancer treatment.

There are many other notable changes in Emerald Mutual Fund Advisers Trust's holdings, such as a 102% increase in its holdings in Lantheus Holdings Inc (SMCI) and a 43.8% decrease in its holdings in Shift4 Payments Inc (FOUR).

In conclusion, Emerald Mutual Fund Advisers Trust has made some significant changes to its holdings in Q1 2023 compared to Q4 2022. Investors and analysts can use this information to track the stocks that mutual funds are buying and selling. It is essential to note that this report only covers stocks worth more than $100 million that are publicly traded in the US, which means it does not show all of the mutual fund company's holdings.